Vicore Pharma postpones publication of year-end report
The reason for postponing the report is the decision to convert the company’s accounting principles to IFRS as per the year-end report for 2018. Conversion to IFRS is an important part of the preparations for the up-listing to the Stockholm Nasdaq main list which is planned to take place during the second half of 2019.
For further information, please contact:
Hans Jeppsson, CFO: +46 70 553 14 65, email@example.com